ArticleCureus2025
Lung Function Changes and Connective Tissue Growth Factor Expression in Idiopathic Pulmonary Fibrosis, Other Progressive Fibrosing Interstitial Lung Diseases, and Post-COVID Fibrosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The clinical course of patients with idiopathic pulmonary fibrosis (IPF) and other progressive interstitial lung diseases (F-ILDs) varies from mild to severe worsening, which makes the development of new diagnostic and prognostic methods even more urgent. A number of studies have shown that plasma connective tissue growth factor (CTGF) is elevated during IPF, and that the levels of this substance are correlated with the changes in forced vital capacity (FVC). The aim of our study was to investigate CTGF levels in patients with F-ILDs group, including its subgroups IPF and other F-ILDs, as well as post-COVID-19 cases, and to assess their association with lung function changes over a 12-month period. Methods A prospective cohort study was conducted with patients observed over 30 months. The involvement period was 18 months, followed by a 12-month observation period. A total of 86 subjects were enrolled in the study. FVC (measured by spirometry), diffusing lung capacity for carbon monoxide (DLCO), and CTGF levels in blood serum (measured by enzyme-linked immunosorbent assay (ELISA)) were assessed at the beginning and end of the study. Results Regression analysis of the correlations between mean serum CTGF levels, FVC, and DLCO changes in the F-ILDs group demonstrated a significant negative correlation between the changes in mean serum CTGF levels, FVC, and DLCO. Similarly, in the IPF, idiopathic nonspecific interstitial pneumonia (iNSIP) and chronic sarcoidosis (IV stage) subgroups, there was a significant negative correlation between changes in mean serum CTGF levels, FVC, and DLCO. However, in the post-COVID-19 group, regression analysis did not reveal any correlations between changes in mean serum CTGF concentrations, FVC, and DLCO. Conclusion Our data suggest a correlation between decreased pulmonary function and increased CTGF levels in patients with IPF and other PPF conditions. Therefore, CTGF emerges as a potential surrogate marker for fibrosis progression in these patients. In contrast, post-COVID-19 fibrosis appears to be a non-progressive fibrotic disease; however, further monitoring is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.